Best Genomics Companies in New York, United States
The 161 best Genomics companies in New York, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kallyope.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in New York
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Kallyope Discovering novel therapeutics for neurological and metabolic diseases | $479M | 37 mo ago | 84 84 → 64 (-24%) | Charles Zuker Co-Founder | 134 patents NK3 receptor modulators for treating neurological and metabolic disorders | — |
| 2 | Neurogene Developer of therapeutics for the treatment of rare neurological disorders | $184M | 66 mo ago | 83 | — | 7 patents Engineered protein therapeutics for T‑reg activation and optimized GALC enzyme replacement. | — |
| 3 | Selecta Biosciences Developer of nanoparticle immunomodulatory drugs for treating multiple diseases | $155M | 70 mo ago | 67 | — | 957 patents Tolerogenic nanocarrier delivery systems for immune‑tolerant protein therapeutics | — |
| 4 | MeiraGTx Developer of gene therapies for ocular and neurodegenerative diseases | $130M | 31 mo ago | 358 358 → 419 (+17%) | — | 14 patents Therapeutic modulation of the retromer complex for neurodegenerative disease treatment | — |
| 5 | Variant Bio Developer of therapeutics for the treatment of orphan indications | $128M | 55 mo ago | 50 | Stephane Castel Co-Founder | — | — |
| 6 | Prevail Therapeutics Developer of gene therapies for treating neurodegenerative and rare diseases | $125M | 86 mo ago | 70 | Asa Abeliovich Founder & CEO | 227 patents Developing gene therapy vectors targeting lysosomal storage disease treatments. | — |
| 7 | Syros Pharmaceuticals Developer of small molecule therapeutics for cancer and genetic diseases | $124M | 45 mo ago | 117 | Conley Chee CEO | 304 patents Patents concentrated in chemistry & materials | — |
| 8 | C2i Genomics Provider of liquid biopsy for post cancer surgery monitoring | $112M | 62 mo ago | 64 | Ezra Sofer Co-Founder | — | — |
| 9 | Applied DNA Sciences Developer of botanical-DNA based security and authentication solutions 24Funding top 24%Product top 24%Tech top 40%Innovation bottom 48% All 10 signals ▾Fundingtop 24% Producttop 24% Techtop 40% Innovationbottom 48% Globalbottom 37% Marketbottom 36% Newsbottom 35% Moatbottom 33% Fin. healthbottom 29% Growthbottom 25% Funding: Raised $98.6M across 17 rounds · 17 rounds over 21 yrs (0.8/yr) Product: 1 product launch event in 12 mo · 7 distinct product lines rank vs industry peers · Fliar Intelligence Index 24/100 | $99M | 8 mo ago | 55 55 → 49 (-11%) | — | — | — |
| 10 | Volastra Developer of therapeutics for cancer treatment 40Funding top 24%Talent top 28%Moat top 39%Tech bottom 48% All 6 signals ▾Fundingtop 24% Talenttop 28% Moattop 39% Techbottom 48% Globalbottom 37% Marketbottom 31% Funding: Raised $87.2M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 40/100 | $87M | 9 mo ago | 21 21 → 41 (+95%) | Samuel Bakhoum Co-Founder | — | 1 job opening |
| 11 | Rocket Pharma Developer of gene-modified cell therapies for the treatment of rare diseases 60Funding top 24%Tech top 32%Market top 42%News top 46% All 7 signals ▾Fundingtop 24% Techtop 32% Markettop 42% Newstop 46% Moattop 48% Growthtop 50% Globalbottom 32% Funding: Raised $83.2M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Tech: 54 technologies across 5/8 capability areas · Cloud: Akamai, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 60/100 | $83M | 18 mo ago | 268 268 → 222 (-17%) | — | — | 1 internship |
| 12 | BioArray Solutions Beadchip for biomolecular analysis | $57M | 228 mo ago | 28 | Jeffrey Binder CEO | 288 patents Multiplexed nucleic‑acid detection and typing using micro‑particle array platforms | — |
| 13 | Gotham Therapeutics Developer of therapeutics for cancer | $54M | 92 mo ago | 4 | — | — | — |
| 14 | Codagenix Developer of live-attenuated viral vaccines using proprietary SAVE technology 62Patents top 19%Moat top 21%Innovation top 24%Talent top 28% All 9 signals ▾Patentstop 19% Moattop 21% Innovationtop 24% Talenttop 28% Fundingtop 30% Marketbottom 49% Globalbottom 42% Techbottom 38% Newsbottom 27% Patents: 127 patents matched (strict assignee match) · 91 filings since 2022 vs 36 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 127 patents rank vs industry peers · Fliar Intelligence Index 62/100 | $47M | 14 mo ago | 41 | — | 127 patents Live-attenuated viral vaccine design using codon deoptimization and recombinant virus platforms | — |
| 15 | Envisagenics AI-driven biotechnology company that focuses on the discovery and development of novel RNA splicing… | $47M | 24 mo ago | 40 | Martin Akerman Co-Founder & CTO | 19 patents Cancer immunotherapy via neoantigen discovery and splicing‑based biomarker platforms | — |
| 16 | Provista Diagnostics Molecular oncology diagnostics company | $42M | 97 mo ago | 2 | — | 22 patents Cancer biomarker diagnostics for early detection of breast and ovarian cancers | — |
| 17 | IVERIC bio Developer of gene therapy solutions to treat retinal diseases | $35M | 91 mo ago | 94 | — | — | — |
| 18 | Phosphorus Provider of next-generation diagnostics and tools for clinicians and researchers | $31M | 70 mo ago | 28 | — | — | — |
| 19 | Celmatix Pioneering ovarian health therapeutics for women's unique biological needs | $25M | 102 mo ago | 27 27 → 15 (-44%) | Piraye Beim Founder and CEO | 136 patents FSH receptor modulators for fertility and peripheral melatonin receptor agonist delivery | — |
| 20 | AcuamarkDx Provider of non-invasive screening test for early detection of cancer | $20M | 24 mo ago | 6 | Bernard Peperstraete Cofounder & CEO | — | — |
| 21 | Genoplan Developer of genetic test kits for health analysis | $20M | 93 mo ago | 16 | — | 11 patents AI-based polygenic risk scoring and disease risk prediction using deep learning models | — |
| 22 | Nucleus Genomics Provider of genetic testing kits for rare variant analysis | $18M | 16 mo ago | 9 | Kian Sadeghi Founder & CEO | — | 1 partnership |
| 23 | Redpin Therapeutics Developer of cell therapies for Neurological and Psychiatric disorders | $17M | 75 mo ago | 10 | — | — | — |
| 24 | Gencove Cloud platform for personal genomics | $16M | 55 mo ago | 31 | — | 2 patents Integrated low‑pass whole‑genome and targeted DNA sequencing for comprehensive genomic analysis | — |
| 25 | Jan Biotech Provider of diagnostic assays for the detection of infectious diseases 10Funding top 42%Talent bottom 45%Tech bottom 34%Global bottom 29% All 5 signals ▾Fundingtop 42% Talentbottom 45% Techbottom 34% Globalbottom 29% Marketbottom 14% Funding: Raised $13.4M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 10/100 | $13M | 9 mo ago | 6 | Jennifer Nichols President/Co-Founder | — | — |
| 26 | Newtopia Provider of health management platform for employers and insurers | $11M | 27 mo ago | 121 | — | — | — |
| 27 | Biotia Provider of sequencing-based solutions for hospitals | $10M | 45 mo ago | 17 | Christopher Mason Co-Founder | — | 1 award |
| 28 | Phoenix Nest Biotech pioneering treatments for Sanfilippo Syndrome, an ultra-rare genetic disease | $9M | 23 mo ago | 11 | — | — | — |
| 29 | OmniSeq Labcorp Oncology: Advancing cancer care through diagnostics, research, and precision medicine | $9M | 84 mo ago | 57 | — | 25 patents AI-driven cancer genomics analytics for biomarkers, ancestry inference, and therapy selection | — |
| 30 | Aptamatrix Developer of next generation technology based diagnostic tools | $9M | 14 mo ago | 6 | Philip Borer Co-Founder & President | — | — |
| 31 | KellBenx Non-invasive prenatal diagnosis for specific genetic and other heritable disorders. | $8M | 80 mo ago | 5 | Hassan Bennani CEO | 38 patents Prenatal diagnostics: isolating and detecting fetal nucleated red blood cells using antibodies and filtration. | — |
| 32 | Melonfrost Operator of an online platform providing various casino-style games | $7M | 40 mo ago | 13 | Luc Harrigan Co-Founder | 10 patents Advanced bioreactor hardware and AI-driven control of microbial evolution | — |
| 33 | Cyprium Developer of therapeutics for rare pediatric diseases | $7M | 56 mo ago | — | Lung S Yam Co-Founder & CEO | — | — |
| 34 | Summit Biomedical Imaging Developer of diagnostic solutions for the early detection of cancer diseases | $4M | 15 mo ago | 3 | Thomas Reiner Co-Founder & Scientific Advisor | — | — |
| 35 | Episteme Prognostics Developer of precision therapeutics for pancreatic cancer | $4M | 37 mo ago | 2 | Surajit Dhara Founder & CEO | 6 patents Epigenomic profiling of chromatin accessibility using qPCR‑based array assays | — |
| 36 | Exavir Developer of therapeutics for the treatment of viral diseases | $4M | 34 mo ago | 3 | Howard Gendelman Co-Founder | — | — |
| 37 | Chimerna Developer of RNA therapeutics | $3M | 16 mo ago | — | Brian Pickering CEO | — | — |
| 38 | Isabl Developer of a medical diagnosis platform to analyze genome of cancer patients | $3M | 38 mo ago | 5 | Juan Medina Co-Founder and CTO | — | — |
| 39 | OyaGen Drug discovery and development for infectious diseases and cancer therapeutics | $3M | 13 mo ago | 4 | Harold Smith founder and CEO of OyaGEn | 55 patents Antiviral small‑molecule therapeutics targeting viral replication enzymes and entry mechanisms | — |
| 40 | RUMI Scientific Provider of proprietary human stem cell platform for screening genetic diseases | $2M | 25 mo ago | 6 | Ali Brivanlou Co-Founder | — | — |
| 41 | Mirimus Accelerating drug discovery with precision preclinical services and innovative disease models | $2M | 20 mo ago | 85 | Prem Premsrirut President/CEO | 21 patents RNAi therapeutics: engineered amiRNA/miRNA design, regulation, and interferon decoy applications | — |
| 42 | StemCultures Controlled-release growth factors for cell culture, improving consistency and quality | $2M | 38 mo ago | 12 | — | — | — |
| 43 | Reme-D.Inc Developer of diagnostic kits for both human and animal diseases 27Patents top 30%Global top 38%Innovation top 41%Funding top 44% All 7 signals ▾Patentstop 30% Globaltop 38% Innovationtop 41% Fundingtop 44% Talentbottom 49% Techbottom 30% Marketbottom 25% Patents: 42 patents matched (strict assignee match) · 10 filings since 2022 vs 6 in 2017-21 Global: Patents filed in 3 jurisdictions · Investors from 3 countries beyond United States rank vs industry peers · Fliar Intelligence Index 27/100 | $2M | 2 mo ago | — | Salma Tammam Founder & CEO | 42 patents Hydraulic control valves and pistons for rotary steerable drilling tools | — |
| 44 | PAVmed Developer of medical devices and biomarkers to detect various diseases | $845K | 4 mo ago | 107 | — | 50 patents Minimally invasive catheter systems for fluid control and fibrous tissue division. | — |
| 45 | Directseq Biosciences Provider of next-generation mass spectrometry-based RNA sequencing | $837K | 10 mo ago | — | Shenglong Zhang Founder & President | — | — |
| 46 | Lixte Developer of drugs to treat cancer | $710K | 11 mo ago | 3 | — | — | — |
| 47 | Epitor Therapeutics Developer of therapeutics based on gene editing technologies | $698K | 21 mo ago | — | Megan McGill CEO | — | — |
| 48 | Helex Provider of next-generation gene-editing therapies | $250K | 7 mo ago | 22 | Anirudh Nishtala Co-Founder & COO | 8 patents Lipid nanoparticle delivery systems for tissue-specific CRISPR gene editing therapies. | — |
| 49 | Signatur Biosciences Developer of molecular diagnostic kits compatible with standard PCR equipment | $125K | 12 mo ago | 6 | Dame Stevens Co-Founder | — | — |
| 50 | Humane Genomics Developer of cancer therapeutics using the oncolytic virus | $125K | 16 mo ago | 8 | Chad Moles Co-Founder & CSO | 10 patents Engineered oncolytic viruses and modular viral genome platforms for targeted cancer therapy | — |
Top 12 Genomics companies in New York
#1
Public · Stony Brook, New York · founded 1983 · 55 employees$98.6Mraised▾
Developer of botanical-DNA-based security and authentication solutions The company has developed a proprietary line of DNA embedded biotechnology for corporations and government agencies that require monitoring and enforcement support. It has developed a security solution to protect corporate and intellectual property from counterfeiting and fraud.
- Sep 2025Post IPO$58M
- Oct 2020Post IPO$1.2M
- Jun 2020Grant (prize money)$40K
- Aug 2019Post IPO$418K
#2
Series B · New York City, New York · founded 2019 · 21 employees$87.2Mraised▾
Developer of therapeutics for cancer treatment. The company is developing compounds to target chromosomal instability and related pathways to inhibit genomic instability and disease progression. It also developing proprietary imaging technologies to identify chromosomal instability cancers.
- Sep 2025Series B$30.1M
- May 2024Series A$15M
- Mar 2023Series A$60.2M
- Apr 2021Seed—
#3
Series B · Stony Brook, New York · founded 2011 · 41 employees$47.1Mraised▾
Developer of live-attenuated viral vaccines using proprietary SAVE technology. The SAVE platform relies on synthetic biology and re-design of the target virus' entire genome to yield a vaccine strain. All pipeline vaccines are currently in preclinical stages targeting seasonal influenza, dengue virus (DEV), respiratory syncytial virus (RCV), and pandemic influenza.
- Apr 2025Grant (prize money)$4.4M
- Oct 2023Grant (prize money)$10M
- Feb 2023Series B$25M
- Jul 2020Grant (prize money)$4.8M
#4
Funding Raised · Ithaca, New York · founded 2014 · 6 employees$13.4Mraised▾
Provider of diagnostic assays for the detection of infectious diseases. The company offers novel molecular in vitro assays for clinical diagnosis and quantification of latent infections such as HIV-1, as well as detection of aggressive cancer (ex., prostate) and cancer treatment monitoring.
- Aug 2025Grant (prize money)$3.3M
- Feb 2025Grant (prize money)$300K
- Feb 2025Grant (prize money)$3.3M
- Sep 2023Grant (prize money)$300K
#5
Public · New York City, New York · founded 2015 · 268 employees$83.2Mraised▾
Developer of gene-modified cell therapies for the treatment of rare diseases. It offers adeno-associated viral and lentil virus gene therapies which include RP-L02 for Fanconi anemia, RP-L201 for leukocyte adhesion deficiency, RP-L301 for pyruvate kinase deficiency, RV-l501 for Danon disease, RP-A601 for PKP2-ACM, and others.
- Dec 2024Post IPO$5M
- Aug 2021Post IPO$26.4M
- Nov 2020Grant (prize money)$3.7M
- Apr 2019Grant (prize money)$6.5M
#6
Seed · New York City, New York · founded 2022$1.5Mraised▾
Developer of diagnostic kits for both human and animal diseases. It offers kits for nucleic acid extraction, amplification, sequencing, and detection to diagnose both infectious and non-infectious diseases.
- Apr 2026Seed$500K
- Nov 2023Grant (prize money)$10K
- Seed$1M
#7
Public · New York City, New York · founded 2014 · 107 employees$845Kraised▾
Developer of medical devices and biomarkers to detect various diseases. The products developed by the company include "CarpX" a minimally invasive device to treat carpal tunnel syndrome, "PortIO" a novel, implantable, intraosseous vascular access device, and "DisappEAR" antimicrobial resorbable ear tubes, and many more.
- Feb 2026Post IPO$30M
- Feb 2025Post IPO$2.4M
- Jan 2025Post IPO$2.7M
- Sep 2024Grant (prize money)$892.1K
#8
Funding Raised · Syracuse, New York · founded 2003 · 6 employees$8.6Mraised▾
AptaMatrix is a biotechnology company focused on developing next-generation technology (High Throughput Screening of Aptamers (HTSA)) based on new tools to accelerate the aptamer's discovery. The company is developing an aptamer-based platform "AlloSwitch" sensor technology that can facilitate drug discovery and rapid detection of chemical and biological analytes. The company claims that using their AptaMatirx's proprietary workflow, the time required for aptamer discovery can be reduced to 2 weeks which can be further reduced to 3 days in the future. In addition, the company provides consulting and technical support to both academic and commercial deep-sequencing projects.
- Apr 2025Grant (prize money)$2M
- Sep 2020Grant (prize money)$2M
- Jul 2016Grant (prize money)$176.8K
- Sep 2010Grant (prize money)$1.1M
#9
Series A · Manhattan, New York · founded 2021 · 9 employees$18Mraised▾
Provider of genetic testing kits for rare variant analysis. The company offers direct to consumer genetic testing platform that provides genetic risk and disposition score analyses on an extensive number of diseases and traits by leveraging whole-genome sequencing (WGS).
- Jan 2025Series A$14M
- Jul 2022Series A$14M
- Dec 2021Seed$3.5M
#10
Series D · New York City, New York · founded 2014 · 84 employees$479Mraised▾
Discovering novel therapeutics for neurological and metabolic diseases. The company focuses on addressing significant health challenges by developing effective and well-tolerated agents. Utilizing the Klarity Platform, scientists investigate medicines targeting metabolism, including type 2 diabetes and obesity, and neurological disorders like migraine and pain. The company pursues innovative approaches to medicine discovery, integrating technologies for differentiated therapeutic development. With a team of scientists and drug developers, the company fosters a culture of innovation and collaboration to advance human health. The company operates in the pharmaceutical and biotechnology sectors, focusing on research and development to create solutions for unmet medical needs. The company's work has a direct social impact by aiming to improve the lives of patients and families affected by these diseases.
- May 2023Grant (prize money)$8.2M
- Feb 2022Series D$236M
- Mar 2020Series C$112M
- Dec 2018Series B$21M
#11
Seed · Rochester, New York · founded 2003 · 4 employees$2.8Mraised▾
Drug discovery and development for infectious diseases and cancer therapeutics. The company focuses on identifying novel therapeutic indications and IND-enabling lead compounds for licensing or partnering. Their expertise spans assay development, screening, and mechanistic studies, offered as a fee-for-service. They develop antiviral and oncology therapeutics, targeting mechanisms responsible for tumor growth and progress. The company seeks collaborators for assay development and drug discovery services, aiming to deliver new therapeutic solutions for clinical development and commercialization. They have High Content Screening (HCS) aspirations and plan to expand screening capabilities. Their lead compounds address HIV, Ebola, and COVID-19. They are involved in preclinical drug discovery, lead compound optimization, and offer services in cell biology, virology, and structural biology. They are based on assay development technology and academic work on gene editing enzymes.
- May 2025Grant (prize money)$597K
- Aug 2023Grant (prize money)$597K
- Jul 2020Grant (prize money)$572.9K
- Aug 2018Grant (prize money)$600K
#12
Funding Raised · New York City, New York · founded 2016 · 3 employees$4.1Mraised▾
Developer of diagnostic solutions for the early detection of cancer diseases. The company has developed a fluorescent small molecule, PARPi-FL by using propitiatory technology that helps to detect early stage of PARP1, which is common in certain cancers. It also helps in diagnosing In vivo oral cancer, Ex vivo cervical cancer, Ex vivo esophageal cancer, Ex vivo breast cancer, and more.
- Mar 2025Grant (prize money)$1.8M
- Sep 2020Grant (prize money)$1.8M
- Mar 2019Grant (prize money)$300K
- Sep 2018Grant (prize money)$299.9K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in the United States
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,110 United States-affiliated papers.
- Harvard University633
- Broad Institute433
- Howard Hughes Medical Institute318
- Stanford University287
- Johns Hopkins University287
- Gene83→532
- Transcriptome25→436
- Genome117→419
- Disease6→218
- Immune system11→219
- Disease17→407
- Immune system4→266
- Gene38→281
- Transcriptome13→238
- Biomarker2→208
- Disease27→311
- Immune system6→152
- Cancer17→130
- Clinical trial4→111
- Biomarker2→92
Where bioinformatics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in the United States
United States bioinformatics patent filing is accelerating — 246 filings from 64 assignees (2016–2025), led by Edico Genome, Illumina, UNIV Washington; annual filings 22→23.
- Edico Genome129
- Illumina60
- UNIV Washington18
- Nantomics9
- Baluch Mohamed Khoso7
- Genomsys7
- Microsoft6
- Contamination Source Identificat5
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.